Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 88

Sort by

Sort Order Select

Journal Articles

Droplet digital PCR improves measurable residual disease detection and predicts relapse in KMT2A-rearranged leukemia after allogeneic hematopoietic stem cell transplantation: A prospective study

Ya Luo, Ya-Zhen Qin, Xiaosu Zhao, Ying-Jun Chang, Jing Liu, Xiao-Dong Mo, Yuqian Sun, Yu Wang, Lanping Xu, Xiaohui Zhang, Xiaojun Huang, Meng Lv

Blood (2025) 146 (Supplement 1): 3518.

https://doi.org/10.1182/blood-2025-3518

Published: 2025

Journal Articles

Isatuximab (Isa) subcutaneous (SC) via an on-body injector (OBI) vs isa intravenous (IV), plus pomalidomide and dexamethasone (Pd) in relapsed/refractory multiple myeloma (RRMM): East asia subgroup results from the randomized, non-inferiority, phase 3 iraklia study

Blood (2025) 146 (Supplement 1): 5819.

https://doi.org/10.1182/blood-2025-5819

Published: 2025

Journal Articles

Chidamide with the methotrexate, ifosfamide, etoposide, doxorubicin liposomes, and dexamethasone (MIEDD) regimen improves efficacy and safety in newly diagnosed primary CNS T-cell lymphoma

Jing Liu, Xuefei Sun, Qu Cui, Yuchen Wu, Yuedan Chen, Ruixian Xing, Wenyuan Lai, Xueyan Bai, Jun Qian, Qing Liu, Huixiu Han, Lin Fu, Yuanbo Liu

Blood (2025) 146 (Supplement 1): 5418.

https://doi.org/10.1182/blood-2025-5418

Published: 2025

Journal Articles

Ponatinib alleviates CAR-T cell exhaustion and remodels the immune microenvironment: A promising combination strategy for relapsed/refractory b-ALL

Yi Zhou, Liwen Wang, Linzhi Xie, Qian Cheng, Jing Liu, Fangping Chen, Rong He, Xin Li

Blood (2025) 146 (Supplement 1): 2331.

https://doi.org/10.1182/blood-2025-2331

Published: 2025

Journal Articles

Fus::ERG fusion represents adverse-plus risk group in AML patients: Evidence from a registry-based matched cohort Study

Yi-Han Yang, Meng Lv, Jia Chen, Jing Liu, Xiaohui Zhang, Lanping Xu, Xi Zhang, Daihong Liu, Depei Wu, Xiaojun Huang

Blood (2025) 146 (Supplement 1): 1706.

https://doi.org/10.1182/blood-2025-1706

Published: 2025

Journal Articles

Oral etoposide vs intravenous daunorubicin plus ATRA-RIF as induction therapy for low-risk acute promyelocytic leukemia: A phase II randomized controlled Trial

Xiaolu Zhu, Zhao Ting, Wen-Bing Duan, Qi Chen, Jing Liu, Wen-Jing Yu, Xiaosu Zhao, Ya-Zhen Qin, Hong-Xia Shi, Ying-Jun Chang, Xiaojun Huang, Hao Jiang

Blood (2025) 146 (Supplement 1): 1671.

https://doi.org/10.1182/blood-2025-1671

Published: 2025

Journal Articles

Outcomes and risk factors of second allogeneic hematopoietic stem cell transplantation in patients with relapsed hematological malignancy after first transplantation

Xiaolu Zhu, Hai-Xia Fu, Jing Liu, Zhengli Xu, Yuqian Sun, Meng Lv, Xiao-Dong Mo, Yi-Fei Cheng, Lanping Xu, Xiaohui Zhang, Xiaojun Huang, Yu Wang

Blood (2025) 146 (Supplement 1): 6047.

https://doi.org/10.1182/blood-2025-6047

Published: 2025

Journal Articles

Preliminary results of a first-in-human, Phase 1 study of GLB-002, a novel molecular glue degrader of IKZF1/3, in patients with relapsed or refractory non-Hodgkin lymphoma

Ningjing Lin, Keshu Zhou, Quande Lin, Lihua Qiu, Zhiming Li, Wei Yang, Yuerong Shuang, Jian Zhang, Hongyan Tong, Hongmei Jing, Peiqi Zhao, Jing Liu, Hong Li, hongli zhang, Liqiang Fu, Gang Lu, Yuqin Song

Blood (2025) 146 (Supplement 1): 5368.

https://doi.org/10.1182/blood-2025-5368

Published: 2025

Journal Articles

Next-day manufactured CD19 CAR-T cells exhibit superior persistence compared to conventional CAR-T therapy in R/R B-ALL

Meng Lv, Xu-Ying Pei, Yan-Ping Ding, Zhipeng Zhou, Luhan Deng, Zhuo-Jun Liu, Jing Liu, Leping Zhang, Qian Jiang, Xiaohui Zhang, Xin-An Lu, Xiao-Zheng Zhao, Guang-Hua Liu, Ting He, Xiaojun Huang, Xiangyu Zhao

Blood (2025) 146 (Supplement 1): 2407.

https://doi.org/10.1182/blood-2025-2407

Published: 2025

Journal Articles

Vennetoclax combined with decitabine, cytarabine, aclacinomycin and granulocyte colony-stimulating factor as induction regimen achieved high response rate in newly diagnosed adverse risk Acute Myeloid Leukemia

Wenbing Duan, Ying Wu, Wen-Jing Yu, Qi Chen, Zhao Ting, Jing Liu, Le-Qing Cao, Ying-Jun Chang, Xiaosu Zhao, Xiaojun Huang, Hao Jiang

Blood (2025) 146 (Supplement 1): 1611.

https://doi.org/10.1182/blood-2025-1611

Published: 2025

Journal Articles

Oral VP16 combined with ATRA and realgar-indigo naturalis formula as complete oral induction regimen is an fast，safe and effective regimen during induction to reduce mortality in high-risk acute promyelocytic leukemia

Wenbing Duan, Qi Chen, Wen-Jing Yu, Xiaolu Zhu, Jing Liu, Zhao Ting, Xiaosu Zhao, Ya-Zhen Qin, Guorui Ruan, Ying-Jun Chang, Xiaojun Huang, Hao Jiang

Blood (2025) 146 (Supplement 1): 6966.

https://doi.org/10.1182/blood-2025-6966

Published: 2025

Journal Articles

Venetoclax, cladribine plus low-dose cytarabine for relapsed/refractory Acute Myeloid Leukemia: A multicenter, randomized phase II Study

Han-Yu Cao, Fangtong Liu, Kai-Wen Tan, Zi-Hao Wang, Si-Man Huang, Chao-Ling Wan, Yuan-Hong Huang, Mei-Jing Liu, Zhen Yao, Zheng Li, Ming-Zhu Xu, Hai-Xia Zhou, Haiping Dai, Shengli Xue

Blood (2025) 146 (Supplement 1): 5202.

https://doi.org/10.1182/blood-2025-5202

Published: 2025

Journal Articles

Combination therapy with methotrexate, ifosfamide, cytarabine, dexamethasone and rituximab (R-MIAD) improves clinical outcomes in primary central nervous system lymphoma: A monocentric retrospective observational study

Yuedan Chen, Qu Cui, Jun Qian, Wenyuan Lai, Xueyan Bai, Jing Liu, Ruixian Xing, Huixiu Han, Qing Liu, Yuchen Wu, Yuanbo Liu, Xuefei Sun, Lin Fu

Blood (2025) 146 (Supplement 1): 3694.

https://doi.org/10.1182/blood-2025-3694

Published: 2025

Journal Articles

Inhibition of terminal complement complex formation alleviates murine antibody-mediated TRALI

Dawei Chen, Huaqin Liang, Xiuzhang Xu, Wenjie Xia, Xin Ye, Yalin Luo, Jiansen He, Yaori Xu, Jing Liu, Hui Ren, Shengxue Luo, Trent M. Woodruff, Wioleta M. Zelek, B. Paul Morgan, Rick Kapur, Sentot Santoso, Yongshui Fu

Blood (2025) 146 (6): 759–764.

https://doi.org/10.1182/blood.2024028012

Published: 2025

Includes: Supplemental data

Journal Articles

Targeting Enterobacter cloacae attenuates osteolysis by reducing ammonium in multiple myeloma

Blood (2025) 145 (17): 1876–1889.

https://doi.org/10.1182/blood.2024025694

Published: 2025

Includes: Supplemental data

Journal Articles

Subgroup Analyses of Phase 2 Study: Evaluating the Efficacy of Fully Human BCMA-Targeting CAR T Cells (Zevorcabtagene Autoleucel) in Patients with Relapsed/Refractory Multiple Myeloma

Blood (2024) 144 (Supplement 1): 4762.

https://doi.org/10.1182/blood-2024-204620

Published: 2024

Journal Articles

Impact of CAR T-Cell Persistence on Clinical Outcomes in Relapsed/Refractory Multiple Myeloma: Insights from the Phase 2 Fumanba-1 Study

Chunrui Li, Dehui Zou, Di Wang, Baijun Fang, He Huang, Jianyong Li, Bing Chen, Jing Liu, Xi Zhang, Yujun Dong, Kai Hu, Peng Liu, Jianqing Mi, Kaiyang Ding, Zhenyu Li, Qie Dong, Fuyuan Zhang, Guang Hu, Lu-Gui Qiu

Blood (2024) 144 (Supplement 1): 4761.

https://doi.org/10.1182/blood-2024-204355

Published: 2024

Journal Articles

HDAC Inhibitor Effectively Reverses Stemness Transformation of ETV6::Mecom -Positive Leukemia Cells By Upregulating CDKN1C

Yuchao Hao, Jing Liu, Jiayin Zhou, Jiong Hu, Jinsong Yan

Blood (2024) 144 (Supplement 1): 5743.

https://doi.org/10.1182/blood-2024-209276

Published: 2024

Journal Articles

HLTF Regulates Erythroid Differentiation through Transcription Factors and Chromatin Landscape Modulation

Han Gong, Bin Hu, Wenwen Xu, Pan Wang, Maohua Li, Ling Nie, Huifang Zhang, Li Liu, Yue Sheng, Long Liang, Xu Han, Mohandas Narla, Jing Liu

Blood (2024) 144 (Supplement 1): 3845.

https://doi.org/10.1182/blood-2024-207540

Published: 2024

Journal Articles

SHMT2-Folate-Folate Receptor Axis Impaired Erythropoiesis in Myelodysplastic Syndrome

Chaoying Yang, Haobo Li, Yanpeng Wang, Ling Nie, Zeyuan Wang, Zhiming Guo, Xu Han, Xiuli An, Jing Liu, Ji Zhang

Blood (2024) 144 (Supplement 1): 6693.

https://doi.org/10.1182/blood-2024-209287

Published: 2024

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Droplet digital PCR improves measurable residual disease detection and predicts relapse in KMT2A-rearranged leukemia after allogeneic hematopoietic stem cell transplantation: A prospective study

Isatuximab (Isa) subcutaneous (SC) via an on-body injector (OBI) vs isa intravenous (IV), plus pomalidomide and dexamethasone (Pd) in relapsed/refractory multiple myeloma (RRMM): East asia subgroup results from the randomized, non-inferiority, phase 3 iraklia study

Chidamide with the methotrexate, ifosfamide, etoposide, doxorubicin liposomes, and dexamethasone (MIEDD) regimen improves efficacy and safety in newly diagnosed primary CNS T-cell lymphoma

Ponatinib alleviates CAR-T cell exhaustion and remodels the immune microenvironment: A promising combination strategy for relapsed/refractory b-ALL

Fus::ERG fusion represents adverse-plus risk group in AML patients: Evidence from a registry-based matched cohort Study

Oral etoposide vs intravenous daunorubicin plus ATRA-RIF as induction therapy for low-risk acute promyelocytic leukemia: A phase II randomized controlled Trial

Outcomes and risk factors of second allogeneic hematopoietic stem cell transplantation in patients with relapsed hematological malignancy after first transplantation

Preliminary results of a first-in-human, Phase 1 study of GLB-002, a novel molecular glue degrader of IKZF1/3, in patients with relapsed or refractory non-Hodgkin lymphoma

Next-day manufactured CD19 CAR-T cells exhibit superior persistence compared to conventional CAR-T therapy in R/R B-ALL

Vennetoclax combined with decitabine, cytarabine, aclacinomycin and granulocyte colony-stimulating factor as induction regimen achieved high response rate in newly diagnosed adverse risk Acute Myeloid Leukemia

Oral VP16 combined with ATRA and realgar-indigo naturalis formula as complete oral induction regimen is an fast，safe and effective regimen during induction to reduce mortality in high-risk acute promyelocytic leukemia

Venetoclax, cladribine plus low-dose cytarabine for relapsed/refractory Acute Myeloid Leukemia: A multicenter, randomized phase II Study

Combination therapy with methotrexate, ifosfamide, cytarabine, dexamethasone and rituximab (R-MIAD) improves clinical outcomes in primary central nervous system lymphoma: A monocentric retrospective observational study

Inhibition of terminal complement complex formation alleviates murine antibody-mediated TRALI

Targeting Enterobacter cloacae attenuates osteolysis by reducing ammonium in multiple myeloma

Subgroup Analyses of Phase 2 Study: Evaluating the Efficacy of Fully Human BCMA-Targeting CAR T Cells (Zevorcabtagene Autoleucel) in Patients with Relapsed/Refractory Multiple Myeloma

Impact of CAR T-Cell Persistence on Clinical Outcomes in Relapsed/Refractory Multiple Myeloma: Insights from the Phase 2 Fumanba-1 Study

HDAC Inhibitor Effectively Reverses Stemness Transformation of ETV6::Mecom -Positive Leukemia Cells By Upregulating CDKN1C

HLTF Regulates Erythroid Differentiation through Transcription Factors and Chromatin Landscape Modulation

SHMT2-Folate-Folate Receptor Axis Impaired Erythropoiesis in Myelodysplastic Syndrome

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only